Crossmark

Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis (ASQA): A Multicenter Post-marketing Surveillance Study

Crossref DOI link: https://doi.org/10.1007/s12325-020-01611-8

Published Online: 2021-01-11

Published Print: 2021-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gharibdoost, Farhad

Salari, Amir-Hossein

Salesi, Mansour

Ebrahimi Chaharom, Faegheh

Mottaghi, Peyman

Hosseini, Mansour

Sahebari, Maryam

Nazarinia, Mohammadali

Mirfeizi, Zahra

Shakibi, Mohammadreza

Moussavi, Hamidreza

Karimifar, Mansour

Mowla, Karim

Karimzadeh, Hadi

Anjidani, Nassim

Jamshidi, Ahmadreza https://orcid.org/0000-0002-0464-8715
Funding

Funding for this research was provided by:

AryoGen Co.
License Information

Text and Data Mining valid from 2021-01-11

Version of Record valid from 2021-01-11
More Information

Article History

Received: 2 November 2020

Accepted: 16 December 2020

First Online: 11 January 2021

Document is current

Any future updates will be listed below